Patients with worsening chronic HFrEF despite standard therapy may benefit from a novel soluble guanylate cyclase stimulator, vericiguat, a randomised controlled trial shows. The addition of vericiguat to usual care for patients with reduced ejection fraction heart failure (HFrEF) significanly lowered their incidence of death from cardiovascular causes or hospitalisation for heart failure. The phase ...
Victory for novel cyclic GMP–based therapy in worsening HFrEF
By Mardi Chapman
21 May 2020